✦ LIBER ✦

Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal®) in the Elderly

✍ Scribed by Valérie D’Acremont; Christian Herzog; Blaise Genton

Book ID: 111279653
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 127 KB
Volume: 13
Category: Article
ISSN: 1195-1982
DOI: 10.1111/j.1708-8305.2006.00001.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunogenicity and safety of a virosomal

Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal®) in healthy toddlers and children in Chile

✍ S Riedemann; G Reinhardt; H Ibarra; GG Frösner 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

Immunogenicity and safety of a virosomal

Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients

✍ L. Loutan; P. Bovier; C. Herzog 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Immunogenicity and safety of a pediatric

Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children

✍ Rachanee Saksawad; Sasithorn Likitnukul; Boonyarat Warachit; Orrawadee Hanvivatv 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 163 KB

Immunogenicity and safety of a virosomal

Immunogenicity and safety of a virosomal influenza vaccine in HIV-infected children

✍ GV Zuccotti; C Cucchi; D Sala; M Giovannini 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Antibody titres after primary and booste

Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®)

✍ V. Usonis; V. Bakasénas; R. Valentelis; G. Katiliene; D. Vidzeniene; C. Herzog 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Long-term immunogenicity of an inactivat

Long-term immunogenicity of an inactivated virosome hepatitis A vaccine

✍ P.A. Bovier; J. Bock; L. Loutan; T. Farinelli; R. Glueck; C. Herzog 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

## Abstract The aim of this study was to predict the long‐term protection induced after immunisation with inactivated, aluminium‐free virosome hepatitis A vaccine. The study population consisted of adult volunteers enrolled in four different clinical trials. Lower 95% confidence interval limits and